It was the priciest biotech startup sale in North Carolina history. Now five years under Bayer, AskBio advances more AAV gene ...

Nandita Vijayasimha, Bengaluru Friday, January 2, 2026, 08:00 Hrs [IST] ...

The current state of radiotherapeutics is “the isotope wars” according to Jack Hoppin, CEO of Boston’s Ratio Therapeutics.

DUBLIN-- (BUSINESS WIRE)--January 13, 2026-- The "Biomedical and ICT Convergence Market by Technology, Solution and Region 2025-2030" report has been added to ResearchAndMarkets.com's offering.

The Europe image-guided drug delivery market is projected to reach $284.1 million by 2035 from $13.7 million in 2024, growing at a CAGR of 32.01% during the forecast period 2025-2 ...

Reported $4.15 billion (YoY growth of +90%) in preliminary* full-year 2025 global product net sales, inclusive of $1.29 billion in fourth quarter ...

STRM.BIO, a biotechnology company pioneering non-viral delivery technologies for in vivo cell and gene therapy, today ...

Alignment Reached with U.S. FDA on Potential Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) Based on ...

The GLP-1 moment signals how quickly a high-demand therapy can upend established care patterns—and how similar innovations ...

Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to solve the grand challenge of in vivo gene delivery, today announced Dyno-yp2, a novel adeno-associated ...

Sherry Gu, Executive Vice President and CTO at WuXi Biologics, explains the critical challenges of developing bispecific ...